4.7 Review

Coronary Artery Disease in Patients ≥80 Years of Age

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 18, Pages 2015-2040

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.12.068

Keywords

coronary artery disease; geriatric cardiology; octogenarians

Funding

  1. American Medical Association Foundation
  2. Gilead Sciences
  3. Sanofi
  4. GlaxoSmithKline
  5. AstraZeneca
  6. Bayer
  7. Bristol-Myers Squibb
  8. Boehringer Ingelheim
  9. Daiichi-Sankyo
  10. Janssen Pharmaceuticals
  11. Novartis Pharmaceutical Company
  12. Medtronic Foundation
  13. Pfizer
  14. U.S. Food and Drug Administration
  15. National Institutes of Health
  16. Boston Scientific
  17. Lilly
  18. Medtronic
  19. Merck

Ask authors/readers for more resources

Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients >= 80 years of age. Nonetheless, older patients have typically been under-represented in cardiovascular clinical trials. Understanding the pathophysiology, epidemiology, and optimal means of diagnosis and treatment of CAD in older adults is crucial to improving outcomes in this high-risk population. A patient-centered approach, taking into account health status, functional ability and frailty, cognitive skills, and patient preferences is essential when caring for older adults with CAD. The present systematic review focuses on the current knowledge base, gaps in understanding, and directions for future investigation pertaining to CAD in patients >= 80years of age. (C) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available